Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vir Biotechnology's Enterprise Value for the quarter that ended in Jun. 2026 was MXN21,094 Mil.
Vir Biotechnology's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was MXN-5,148 Mil. Vir Biotechnology's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was -21.83%.
The historical rank and industry rank for Vir Biotechnology's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
MEX:VIR'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11880.93 Med: -7.81 Max: 34901.6
Current: -23.93
During the past 9 years, the highest Earnings Yield (Joel Greenblatt) of Vir Biotechnology was 34901.60%. The lowest was -11880.93%. And the median was -7.81%.
MEX:VIR's Earnings Yield (Joel Greenblatt) % is ranked worse than 67.84% of 1340
companies
in the Biotechnology industry
Industry Median: -10.155
vs MEX:VIR: -23.93
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Vir Biotechnology's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Vir Biotechnology (MEX:VIR) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Vir Biotechnology Earnings Yield (Joel Greenblatt) % Related Terms
Vir Biotechnology Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Vir Biotechnology's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vir Biotechnology Earnings Yield (Joel Greenblatt) % Chart
For the Biotechnology subindustry, Vir Biotechnology's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vir Biotechnology Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vir Biotechnology's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Vir Biotechnology's Earnings Yield (Joel Greenblatt) % falls into.
Vir Biotechnology Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Vir Biotechnologys Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Vir Biotechnology's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-5,148 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -21.83% mean?
Vir Biotechnology (MEX:VIR) has a Earnings Yield (Joel Greenblatt) % of -21.83% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Vir Biotechnology and its competitors. According to the industry distribution chart, Vir Biotechnology ranks #909 out of 1340 companies in the Biotechnology industry, placing it in the top 67.8%.
Is Vir Biotechnology's Earnings Yield (Joel Greenblatt) % too high?
Vir Biotechnology's current Earnings Yield (Joel Greenblatt) % is -21.83%. Based on the distribution chart, Vir Biotechnology ranks #909 out of 1340 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vir Biotechnology has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Vir Biotechnology's Earnings Yield (Joel Greenblatt) % compare to AVBP and XNCR?
According to the Biotechnology industry distribution chart, Vir Biotechnology ranks #909 out of 1340 companies for Earnings Yield (Joel Greenblatt) %. This places Vir Biotechnology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Vir Biotechnology and its competitors. Vir Biotechnology's current Earnings Yield (Joel Greenblatt) % is -21.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vir Biotechnology stock overvalued right now?
Vir Biotechnology (MEX:VIR) has a current Earnings Yield (Joel Greenblatt) % of -21.83%. The stock's GF Value™ is MXN764.28, compared to a current price of MXN170.00 — trading 77.8% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -21.83%. Vir Biotechnology's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Vir Biotechnology (MEX:VIR), the current Earnings Yield (Joel Greenblatt) % is -21.83% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vir Biotechnology (MEX:VIR) Overvalued in 2026?
Based on GuruFocus' analysis, Vir Biotechnology stock appears to be undervalued.
The current stock price of MXN170.00 is trading 77.8% below its estimated GF Value™ of MXN764.28.
Key valuation signals for MEX:VIR:
Earnings Yield (Joel Greenblatt) %: -21.83%
GF Value™: MXN764.28 vs. price of MXN170.00 (77.8% below fair value)
No single metric tells the full story. See the MEX:VIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
52GF Score
Get the complete analysis for MEX:VIR
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VIR has been successfully added to your 
